Head to Head Contrast: NovelStem International (NSTM) & Its Peers

NovelStem International (OTCMKTS:NSTM) is one of 78 publicly-traded companies in the “Diagnostics & Research” industry, but how does it compare to its competitors? We will compare NovelStem International to related businesses based on the strength of its risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Earnings and Valuation

This table compares NovelStem International and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NovelStem International	$10,000.00	-$4.19 million	-1.05
NovelStem International Competitors	$849.38 million	$43.67 million	-193.93

NovelStem International’s competitors have higher revenue and earnings than NovelStem International. NovelStem International is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

31.7% of shares of all “Diagnostics & Research” companies are owned by institutional investors. 13.6% of NovelStem International shares are owned by insiders. Comparatively, 24.6% of shares of all “Diagnostics & Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for NovelStem International and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovelStem International	0	0	0	0	N/A
NovelStem International Competitors	78	422	478	7	2.42

As a group, “Diagnostics & Research” companies have a potential upside of 5.71%. Given NovelStem International’s competitors higher possible upside, analysts plainly believe NovelStem International has less favorable growth aspects than its competitors.

Profitability

This table compares NovelStem International and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovelStem International	-9,166.67%	N/A	-73.18%
NovelStem International Competitors	-415.67%	-798.15%	-22.91%

Volatility & Risk

NovelStem International has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, NovelStem International’s competitors have a beta of -0.41, indicating that their average stock price is 141% less volatile than the S&P 500.

Summary

NovelStem International competitors beat NovelStem International on 7 of the 10 factors compared.

NovelStem International Company Profile

NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.